Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
5
×
boston blog main
5
×
life sciences
national blog main
boston top stories
clinical trials
fda
san francisco blog main
boston
deals
investing
national top stories
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
2019
480 biomedical
activism
acute hepatic porphyria
aimmune therapeutics
akouos
allergy
alnylam pharmaceuticals
anaphylaxis
What
treat
5
×
therapeutics
drug
approval
approved
developing
fda
ipo
late
million
raised
therapy
advanced
affects
agency
aimmune
allergy
alnylam’s
americans
analytics
awarded
bff
bio
biofourmis
biotech
company
conference
data
date
deals
debut
developed
devices
devoted
digital
disease
easl
employs
form
frequency
Language
unset
Current search:
treat
×
biotech
×
" boston blog main "
×
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
4 years ago
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More